These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20085605)

  • 21. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Blue-Carba test for rapid detection of carbapenemases in gram-negative bacilli.
    Pasteran F; Veliz O; Ceriana P; Lucero C; Rapoport M; Albornoz E; Gomez S; Corso A;
    J Clin Microbiol; 2015 Jun; 53(6):1996-8. PubMed ID: 25809971
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of carbapenemase-producing gram-negative bacteria using a simplified Carba NP test.
    Yan Q; Liu Q; Li Y; Li H; Liang X; Zou M; Liu WE
    J Microbiol Methods; 2016 Apr; 123():1-3. PubMed ID: 26854838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.
    Moland ES; Hanson ND; Black JA; Hossain A; Song W; Thomson KS
    J Clin Microbiol; 2006 Sep; 44(9):3318-24. PubMed ID: 16954267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002).
    Jones RN; Deshpande LM; Bell JM; Turnidge JD; Kohno S; Hirakata Y; Ono Y; Miyazawa Y; Kawakama S; Inoue M; Hirata Y; Toleman MA
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):289-94. PubMed ID: 15313535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program.
    Mendes RE; Bell JM; Turnidge JD; Castanheira M; Jones RN
    J Antimicrob Chemother; 2009 Jan; 63(1):55-9. PubMed ID: 18957398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007).
    Patzer JA; Dzierzanowska D; Turner PJ
    J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
    J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
    J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accumulation of carbapenemase-producing Gram-negative bacteria in a single patient linked to the acquisition of multiple carbapenemase producers and to the in vivo transfer of a plasmid encoding VIM-1.
    Drieux L; Bourgeois-Nicolaos N; Cremniter J; Lawrence C; Jarlier V; Doucet-Populaire F; Sougakoff W
    Int J Antimicrob Agents; 2011 Aug; 38(2):179-80. PubMed ID: 21570257
    [No Abstract]   [Full Text] [Related]  

  • 39. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.